leon-nanodrugs appoints Dr. Wolfgang Hofmann as Chief Executive Officer
We are pleased to announce the appointment of Dr. Wolfgang Hofmann as its new Chief Executive Officer (CEO). With his extensive experience in scaling life science ventures and leading international teams, Dr. Hofmann will guide LEON through its next phase of growth. Under his leadership, LEON will focus on bringing its breakthrough FR-JET® technology and equipment portfolio to the market.
The company is now entering a pivotal phase, transitioning from development to commercialization. In the coming months, LEON aims to establish key partnerships, expand manufacturing capabilities, and position itself as a leading enabler of high quality GMP nanoparticle manufacturing.
Dr. Hofmann brings 30 years of experience in medicine, medical research, corporate strategy, financing, and operational management within the pharmaceutical and medical technology industries. He began his career at Dana-Farber Cancer Institute and Harvard Medical School, contributing to early gene therapy systems. He later held senior positions at Novartis and executive roles at Fresenius Group, covering M&A, venture capital, and innovation management. As an entrepreneur, he has founded companies and supports nonprofit institutions. Dr. Hofmann holds a medical doctorate from the University of Heidelberg and an executive management degree from Harvard Business School.
About LEON
leon-nanodrugs GmbH is a Munich-based pharmatech company specializing in the development of devices for the encapsulation of genetic material and other pharmaceutical active substances into nanocarriers, such as lipid nanoparticles (LNPs). LEON builds its innovative solutions based on its proprietary FR-JET® Technology. Its portfolio of devices, NANOscreen® for simplified formulation screening, NANOlab® for process development, and NANOme® and NANOus® for GMP aseptic manufacturing, enable faster route to clinical batches and are suitable for both individualised scales and commercial production.
LEON’s platform is aimed at enabling pharma companies, small biotech, research institutes, as well as CDMOs, to take full advantage of the significant progress being made in advanced therapies.
For general information and enquiries please email info@leon-nanodrugs.com